THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Monday, February 28, 2022
Analytical services, more specifically Analytical Research & Development (AR&D), are the foundation of any successful Fill-Finish program
Fremont, CA: Sterile Fill-Finish is one of the most important processes in the parenteral manufacturing process, as it ensures patient safety, pharmacological efficacy, and product quality. A variety of integrated process elements operating in a systematic and coordinated context are required for drug product development and subsequent manufacture. Analytical support is without a doubt one of the most important aspects of the process. Its significance and originality stem from the fact that it is required at every stage of the product's life cycle, from conception to commercialization. AR&D groups are in charge of developing and validating analytical methods that are accurate, precise, dependable, and appropriate for their intended use.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Analytical procedures, which include diverse in-process testing, are used to determine the identity, purity, physical features, and potency of pharmaceuticals. As a result, the methodologies are primarily intended to aid formulation scientists in collecting specific process knowledge. The latter leads to process improvement and the ability to scale up from a modest to a large commercial scale. For formulation development work, having timely access to precise analytical data is critical. To guarantee that analytical procedures suit the specific objectives of each development project, extensive interactions between analytical and formulation scientists are required. Another goal of the AR&D department is to create methods that are robust and repeatable enough to be used in Quality Control labs. AR&D teams are expected to lead these transitional operations and provide guidance to QC teams.
Why AR&D focuses on Robust method development
The pharmaceutical sector is continually changing, and the number of chemicals under investigation continues to rise. As a result, there is a greater need for the development of novel analytical procedures. Each project is distinct. Contract development and manufacturing organizations (CDMO) AR&D scientists must methodically examine each project to decide if there is enough knowledge for a successful tech transfer or if new approaches are required, all while sticking to the customer's project timetable. Another key characteristic of best-in-class AR&D teams is the capacity to show that the analytical approach is scientifically solid, suitable for the purpose, and adaptable.
More in News